A. Swalduz

发表

Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort

L. Delrieu, S. Chabaud, P. Heudel, 2021, Cancers.

Gene signature of circulating platelet‐bound neutrophils is associated with poor prognosis in cancer patients

A. Viari, C. Caux, M. Ardin, 2022, International journal of cancer.

First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data

O. Bylicki, C. Chouaïd, A. Swalduz, 2022, BioDrugs.

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

A. Valipour, A. Addeo, T. Čufer, 2022, Therapeutic Advances in Medical Oncology.

Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study

N. Girard, P. Fournel, R. Descourt, 2022, Therapeutic advances in medical oncology.

Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel

A. Viari, P. Saintigny, O. Trédan, 2022, medRxiv.

Combined proteomic and transcriptomic approaches reveal externalized keratin 8 as a potential therapeutic target involved in invasiveness of head and neck cancers

I. Treilleux, P. Saintigny, D. Goga, 2020, Translational oncology.

Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.

S. Boyault, S. Lantuejoul, C. Caux, 2022, European journal of cancer.

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors

J. Emile, E. Giroux-Leprieur, A. Costantini, 2021, Frontiers in Oncology.

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

J. Blay, I. Ray-Coquard, P. Saintigny, 2020, European Journal of Cancer.

Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?

M. Pérol, A. Swalduz, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay.

D. Planchard, V. Plagnol, P. Saintigny, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

J. Blay, V. Grégoire, B. Fervers, 2021, ESMO open.

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

J. Blay, D. Planchard, J. Mazières, 2020, Clinical Cancer Research.

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

Anne-Laure Désage, S. Ortiz-Cuaran, A. Swalduz, 2022, Frontiers in Oncology.

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer

P. Saintigny, D. Moro-Sibilot, M. Pérol, 2020, Cancers.

[NSCLC and new oncogenic mutations: Diagnosis and perspectives].

N. Girard, D. Moro-Sibilot, J. Remon, 2021, Revue des maladies respiratoires.

The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer

M. Pérol, A. Swalduz, M. Boussageon, 2021, Expert review of anticancer therapy.

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

S. Banerji, A. Valipour, A. Addeo, 2021, Therapeutic advances in medical oncology.

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

D. Planchard, P. Saintigny, L. Lacroix, 2020, PloS one.

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.

D. Planchard, V. Plagnol, J. Adam, 2020, JCO precision oncology.

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).

D. Santamaría, S. Novello, D. Planchard, 2021, Cancer treatment reviews.

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report

M. Pérol, V. Avrillon, A. Swalduz, 2021, JTO clinical and research reports.

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.

J. Grellard, B. Clarisse, P. Tomasini, 2023, European journal of cancer.

Gene signature of circulating platelet‐bound neutrophils is associated with poor prognosis in cancer patients

A. Viari, C. Caux, M. Ardin, 2021, bioRxiv.

Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic

M. Pérol, A. Toffart, T. Pierret, 2023, Respiratory Medicine and Research.

The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.

N. Magné, R. Rivoirard, P. Fournel, 2015, Critical reviews in oncology/hematology.

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.

M. Pérol, V. Avrillon, B. Mastroianni, 2020, Clinical lung cancer.

MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer

D. Planchard, J. Mazières, P. Saintigny, 2019, Journal of Thoracic Oncology.

Occupational asbestos exposure and survival among lung cancer patients.

J. Blay, P. Saintigny, B. Charbotel, 2023, Lung cancer.

37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer

C. Mascaux, V. Gounant, A. Lemaitre, 2022, Annals of Oncology.

Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.

S. Lantuejoul, A. Bouhamama, T. Franceschi, 2022, Clinical lung cancer.

Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.

T. Jatkoe, S. Ou, E. Felip, 2023, Journal of Clinical Oncology.

Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients.

S. Lantuejoul, I. Ray-Coquard, F. de Fraipont, 2019, Future oncology.

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

F. Guisier, R. Descourt, L. Greillier, 2023, Journal of Cancer Research and Clinical Oncology.

Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRASG12C-mutant lung cancer.

C. Mascaux, E. Wasielewski, V. Gounant, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survival of bronchopulmonary cancers according to radon exposure

B. Charbotel, V. Avrillon, T. Coudon, 2023, Frontiers in public health.

Fusion detection and longitudinal circulating tumor DNA (ctDNA) profiling in ALK+ non-small cell lung cancer (NSCLC) patients.

P. Saintigny, D. Pérol, K. Howarth, 2018 .

Treatment sequences in EGFR mutant advanced NSCLC.

A. Swalduz, M. Pérol, M. Wespiser, 2024, Lung cancer.